Abstract | OBJECTIVE: DATA SOURCES: Phase I, II, and III trials and review articles were identified through MEDLINE (1996-January 2015) and PubMed (1996-January 2015), conference abstracts, and US national clinical trials registry, using the keywords NS3/4A protease inhibitor, NS5A inhibitor, NS5B polymerase inhibitor, ABT-450, ABT-267, ABT-333, paritaprevir, ombitasvir, and dasabuvir. STUDY SELECTION AND DATA EXTRACTION: Preclinical, phase I, II, and III studies describing pharmacology, pharmacokinetics, efficacy, safety, and tolerability were identified. DATA SYNTHESIS: CONCLUSION: The regimen consisting of ombitasvir/ paritaprevir/ ritonavir and dasabuvir is highly efficacious in the treatment of HCV genotype 1 infection, with minimal adverse events. It is expected to play an important role in the armamentarium of novel agents that have a high chance of curing HCV infection.
|
Authors | Olga M Klibanov, Stormi E Gale, Barbara Santevecchi |
Journal | The Annals of pharmacotherapy
(Ann Pharmacother)
Vol. 49
Issue 5
Pg. 566-81
(May 2015)
ISSN: 1542-6270 [Electronic] United States |
PMID | 25680759
(Publication Type: Journal Article, Review)
|
Copyright | © The Author(s) 2015. |
Chemical References |
- Anilides
- Antiviral Agents
- Carbamates
- Cyclopropanes
- Drug Combinations
- Lactams, Macrocyclic
- Macrocyclic Compounds
- Sulfonamides
- Tablets
- ombitasvir
- Ribavirin
- Uracil
- Proline
- 2-Naphthylamine
- dasabuvir
- Valine
- Ritonavir
- paritaprevir
|
Topics |
- 2-Naphthylamine
- Anilides
(therapeutic use)
- Antiviral Agents
(therapeutic use)
- Carbamates
(therapeutic use)
- Clinical Trials, Phase I as Topic
- Clinical Trials, Phase II as Topic
- Clinical Trials, Phase III as Topic
- Cyclopropanes
- Drug Combinations
- Drug Resistance, Viral
- Drug Therapy, Combination
- Genotype
- Hepacivirus
(genetics)
- Hepatitis C, Chronic
(drug therapy)
- Humans
- Lactams, Macrocyclic
- Liver Cirrhosis
(drug therapy)
- Macrocyclic Compounds
(therapeutic use)
- Proline
(analogs & derivatives)
- Ribavirin
(therapeutic use)
- Ritonavir
(therapeutic use)
- Sulfonamides
(therapeutic use)
- Tablets
- Uracil
(analogs & derivatives, therapeutic use)
- Valine
|